PMID- 29318593
OWN - NLM
STAT- MEDLINE
DCOM- 20190102
LR  - 20211204
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 180
IP  - 5
DP  - 2018 Mar
TI  - Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib 
      therapy: European recommendations for clinical practice.
PG  - 666-679
LID - 10.1111/bjh.15080 [doi]
AB  - Ibrutinib is indicated in Europe for the treatment of several B-cell 
      malignancies, including chronic lymphocytic leukaemia (CLL). However, despite the 
      high efficacy and favourable toxicity profile of ibrutinib, recent data suggest 
      that it is not always administered optimally in clinical practice, with an 
      increased tendency for dose reduction and a higher frequency of discontinuation. 
      An expert panel of European haematologists was convened to identify practical 
      issues pertinent to physicians involved in the therapeutic management of 
      ibrutinib-treated CLL patients and here we outline the findings. Practical 
      management recommendations are given for treating patients with ibrutinib and 
      clinical considerations for the management of adverse events (AEs) that can be 
      associated with ibrutinib treatment are addressed. This article highlights that 
      patients should be monitored for treatment emergent adverse events, most of which 
      are mild, transient and generally occur early in therapy and that, even with more 
      challenging AEs, patients can often be maintained on therapy with minimal 
      disruption through careful management. The necessity to use the correct ibrutinib 
      dose, along with increased awareness, vigilance, mitigation and management of 
      AEs, are all recommended to maximise outcomes for CLL patients treated with 
      ibrutinib.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Gribben, John G
AU  - Gribben JG
AUID- ORCID: 0000-0002-8505-7430
AD  - Barts Cancer Institute, Queen Mary University of London, London, UK.
FAU - Bosch, Francesc
AU  - Bosch F
AD  - Department of Haematology, Vall d'Hebron University Hospital, Barcelona, Spain.
FAU - Cymbalista, Florence
AU  - Cymbalista F
AD  - U978 Institut National de la Sante et de la Recherche Medicale, Bobigny, France.
AD  - Labex Inflamex, Universite Paris 13, Sorbonne Paris Cite, Bobigny, France.
AD  - Hopital Avicenne, Assistance Publique-Hopitaux de Paris, Bobigny, France.
FAU - Geisler, Christian H
AU  - Geisler CH
AD  - Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
FAU - Ghia, Paolo
AU  - Ghia P
AD  - Strategic Research Programme on CLL, IRCCS San Raffaele Hospital, Milan, Italy.
AD  - Universita Vita-Salute San Raffaele, Milan, Italy.
FAU - Hillmen, Peter
AU  - Hillmen P
AD  - St James' Institute of Oncology, University of Leeds, Leeds, UK.
FAU - Moreno, Carol
AU  - Moreno C
AD  - Department of Haematology, Hospital de la Santa Creu Sant Pau, Autonomous 
      University of Barcelona, Barcelona, Spain.
FAU - Stilgenbauer, Stephan
AU  - Stilgenbauer S
AD  - Department of Internal Medicine III, University of Ulm, Ulm, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180109
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Anticoagulants)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Piperidines)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 1X70OSD4VX (ibrutinib)
RN  - JAC85A2161 (Adenine)
SB  - IM
MH  - Adenine/analogs & derivatives
MH  - Anticoagulants/therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Arthralgia/chemically induced
MH  - Atrial Fibrillation/chemically induced
MH  - Diabetes Mellitus, Type 1/chemically induced
MH  - Diarrhea/chemically induced
MH  - Drug Eruptions/etiology
MH  - Drug Interactions
MH  - Exanthema/chemically induced
MH  - Fatigue/chemically induced
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Hypertension/chemically induced
MH  - Infections/chemically induced
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
MH  - Lymphocytosis/chemically induced
MH  - Medication Adherence
MH  - Myalgia/chemically induced
MH  - Piperidines
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Pyrazoles/*therapeutic use
MH  - Pyrimidines/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - European recommendations
OT  - anticoagulation
OT  - bleeding
OT  - chronic lymphocytic leukaemia
OT  - ibrutinib
EDAT- 2018/01/11 06:00
MHDA- 2019/01/03 06:00
CRDT- 2018/01/11 06:00
PHST- 2017/09/14 00:00 [received]
PHST- 2017/10/23 00:00 [accepted]
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
PHST- 2018/01/11 06:00 [entrez]
AID - 10.1111/bjh.15080 [doi]
PST - ppublish
SO  - Br J Haematol. 2018 Mar;180(5):666-679. doi: 10.1111/bjh.15080. Epub 2018 Jan 9.